Ligand Pharmaceuticals Sees Strong Royalty Growth Ahead of Investor Day, Oppenheimer Says
Ligand Pharmaceuticals (LGND) Stock Price Ignores Q3 Earnings Losses And Royalty Strength
RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $357
Ligand Pharmaceuticals Incorporated 2026 Q3 - Results - Earnings Call Presentation
Loading...